ArticleBMC psychiatry2016
The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis.
Article in BMC psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00932529 (Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.), which is not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.Molecular psychiatry · 2022Pooled it
- The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review.Current neuropharmacology · 2018Pooled it
- Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis.Acta neuropsychiatrica · 2019Trial
- Article
- Natural-cause mortality and C-reactive protein levels in patients with schizophrenia spectrum disorders: A prospective total cohort study.Brain, behavior, & immunity - health · 2025Article
- Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia.BMC psychiatry · 2025Article
- Linking Metabolic Disorders and Immune System Phenomena in Schizophrenia: The Role of Adipose Tissue and Inflammation.Biomedicines · 2025Review
- Relationship Between Family Support, C-Reactive Protein and Body Mass Index Among Outpatients with Schizophrenia.Healthcare (Basel, Switzerland) · 2025Article
- Involvement of virus infections and antiviral agents in schizophrenia.Psychological medicine · 2025Review
- Alterations of the IKZF1-IKZF2 tandem in immune cells of schizophrenia patients regulate associated phenotypes.Journal of neuroinflammation · 2024Article
- Inflammatory Biomarkers, Cognitive Functioning, and Brain Imaging Abnormalities in Bipolar Disorder: A Systematic Review.Clinical neuropsychiatry · 2024Review
- Executive functioning trajectories and their prospective association with inflammatory biomarkers in schizophrenia and non-psychiatric comparison participants.Progress in neuro-psychopharmacology & biological psychiatry · 2024Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- Redox and Immune Signaling in Schizophrenia: New Therapeutic Potential.The international journal of neuropsychopharmacology · 2023Review
- Identification of Diagnostic Schizophrenia Biomarkers Based on the Assessment of Immune and Systemic Inflammation Parameters Using Machine Learning Modeling.Sovremennye tekhnologii v meditsine · 2023Article
- A Comparison of the Relationship Between C-Reactive Protein Levels and Cognitive Functions in Patients with Schizophrenia, First-Episode Psychosis, and Healthy Controls.Psychiatry and clinical psychopharmacology · 2022Article
- Haptoglobin in ultra-high risk of psychosis - Findings from the longitudinal youth at risk study (LYRIKS).Brain, behavior, & immunity - health · 2022Article
- Associations between inflammatory marker profiles and neurocognitive functioning in people with schizophrenia and non-psychiatric comparison subjects.Journal of psychiatric research · 2022Article
- Diagnosis of Schizophrenia Based on the Data of Various Modalities: Biomarkers and Machine Learning Techniques (Review).Sovremennye tekhnologii v meditsine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis.
methodsA total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status.
resultsThere was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels.
conclusionsThe findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis.
trial registrationClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.